Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019

Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019

Shots:

  • The P-III study results involves assessing of Taltz in patients with moderate to severe plaque psoriasis for 5yrs.in addition to an extension study UNCOVER-1
  • Collective results: 90%+ maintained skin clearance as measured by PASI 75; @264wks. PASI 75 (94.3); PASI 90 (81.8%); PASI 100 (46.6%), presented at WCD with additional data of UNCOVER-3 study
  • Taltz (80mg/ml, pre-filled syringe) is a mAb act by targeting IL-17A, being studied in 13 clinical studies in 17,000+ patients under Taltz clinical study program and is an approved therapy for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Click here to read full press release/ article | Ref: Eli Lilly | Image: Pinterest